🇺🇸 FDA
Patent

US 10822316

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

granted A61PA61P1/04A61P17/06

Quick answer

US patent 10822316 (3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors) held by Valo Early Discovery, Inc. expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Valo Early Discovery, Inc.
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P1/04, A61P17/06, A61P19/02, A61P19/04